Effects of a conventional mood stabilizer alone or in combination with second‐generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta‐analysis of randomized, placebo‐controlled trials

2021 ◽  
Author(s):  
Taro Kishi ◽  
Kenji Sakuma ◽  
Makoto Okuya ◽  
Yuki Matsuda ◽  
Satoru Esumi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Recurrence Rate ◽  
Second Generation ◽  
Meta Analysis ◽  
Maintenance Phase ◽  
Mood Stabilizer ◽  
Controlled Trials ◽  
Discontinuation Rate ◽  
Bipolar I Disorder ◽  
Second Generation Antipsychotics

Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials

2013 ◽  
Vol 150 (2) ◽  
pp. 408-414 ◽  
Author(s):  
Kesavan Muralidharan ◽  
Mazen Ali ◽  
Leonardo E. Silveira ◽  
David J. Bond ◽  
Konstantinos N. Fountoulakis ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Second Generation ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Second Generation Antipsychotics

scholarly journals Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 27 (3) ◽  
pp. 250-259 ◽  
Author(s):  
Ying-zi Shen ◽  
Ke Peng ◽  
Juan Zhang ◽  
Xiao-wen Meng ◽  
Fu-hai Ji
Keyword(s):  
Systematic Review ◽  
Second Generation ◽  
Meta Analysis ◽  
Adult Patients ◽  
Surgical Patients ◽  
Cochrane Library ◽  
High Dose ◽  
Qtc Interval ◽  
Second Generation Antipsychotics ◽  
The Cochrane Library

Objective: The aim of this systematic review and meta-analysis was to investigate whether or not the use of haloperidol could reduce the incidence of delirium in adult patients. Subjects and Methods: PubMed, Embase, the Cochrane Library, Elsevier, Wiley, and Ovid were searched for randomized controlled trials and prospective interventional cohort studies that compared haloperidol with placebo for delirium prophylaxis or with second generation antipsychotics for delirium treatment. The primary end point was the incidence and severity of delirium. After reviewing 272 relevant articles, 10 studies with 1,861 patients were finally included (haloperidol vs. placebo in 8 studies [n = 1,734], and haloperidol vs. second-generation antipsychotics in 2 studies [n = 127]). Revman 5.3 was used for the data analysis. Results: Compared with placebo, a high dose of prophylactic haloperidol (≥5 mg/day) may help reduce the incidence of delirium in surgical patients (risk ratio 0.50, 95% CI 0.32, 0.79). There were no differences in the duration of delirium, QTc interval prolongation, extrapyramidal symptoms, intensive care unit stay, hospital stay, or mortality between the haloperidol and placebo groups. For delirium treatment, haloperidol exhibited similar effects as the second-generation antipsychotics. Conclusions: In this study, the limited available data revealed that prophylaxis haloperidol at a dose of ≥5 mg/day might help reduce delirium in adult surgical patients. Further outcome studies with larger sample sizes are required to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document